Similar investigations have been performed for subcutaneous treatment with tirzepatide, a combined glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist [29], as well as for the GLP-1RAs liraglutide, exenatide, dulaglutide, and semaglutide [30,31,32,33,34]
BMJ 2023;382:p2019.Article 72
Once-Weekly Injections: Convenient and easy to administer, the injections allow you to stay on track with your weight loss program
Cholecystokinin and gut-brain signalling
Research Verdict: When to Use Each or Both Choose BPC-157 When Research Focuses On: Gastrointestinal healing and protection Tendon and ligament injuries Nerve regeneration and neuroprotection Situations requiring oral administration Protection from NSAID or other toxic damage Choose TB-500 When Research Focuses On: Cardiac tissue repair and cardioprotection Wound healing and scar reduction Systemic anti-inflammatory effects Muscle regeneration Hair follicle research Consider Combination When: Comprehensive tissue repair is the goal (e.g., complex injury involving multiple tissue types) Maximizing angiogenesis AND cell migration is desired Research hypothesis involves sequential healing phases Mechanistic Rationale for Stacking: The combination addresses different phases of healingBPC-157 promotes blood vessel ingrowth and initial cytoprotection, while TB-500 facilitates the cellular repair and remodeling that follows vascularization
These gaps remain open